首页 | 本学科首页   官方微博 | 高级检索  
     


A multi-institutional phase 2 trial of regorafenib in refractory advanced biliary tract cancer
Authors:Richard D. Kim MD  Hanna K. Sanoff MD  Andrew S. Poklepovic MD  Heloisa Soares MD  PhD  Jongphil Kim PhD  Jing Lyu PhD  Yingmiao Liu PhD  Andrew B. Nixon PhD  Dae Won Kim MD
Affiliation:1. Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, Florida, USA;2. Department of Medicine, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, USA;3. Department of Medicine, Virginia Commonwealth University Health System, Richmond, Virginia, USA;4. University of New Mexico Comprehensive Cancer Center, Albuquerque, New Mexico, USA;5. Department of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, Florida, USA;6. Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA
Abstract:
Keywords:biliary tract cancer  chemotherapy-refractory  cholangiocarcinoma  gallbladder cancer  regorafenib
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号